Ark Therapeutics Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Private, Subsidiary
- Established
- 2018-04-30
- Employees
- -
- Market Cap
- -
Adenovirus Vascular Endothelial Growth Factor (VEGF) Therapy in Vascular Access - Novel Trinam AGainst Control Evidence
Phase 3
Terminated
- Conditions
- End Stage Renal Disease
- Interventions
- Procedure: Graft placement surgery plus Trinam therapy
- First Posted Date
- 2009-05-08
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- Ark Therapeutics Ltd
- Target Recruit Count
- 250
- Registration Number
- NCT00895479
- Locations
- 🇺🇸
Texas Tech University Medical Center, Lubbock, Texas, United States
🇺🇸Ohio State University Division of Nephrology, Columbus, Ohio, United States
🇺🇸Harborview Medical Center, Seattle, Washington, United States
© Copyright 2025. All Rights Reserved by MedPath